Chi H - Search Results

1

Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B.

Shen S, Wong GL, Kuang Z, van Campenhout MJH, Fan R, Wong VW, Yip TC, Chi H, Liang X, Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J, Sun J, Chan HL. Shen S, et al. Among authors: chi h. J Med Virol. 2020 Aug;92(8):1206-1213. doi: 10.1002/jmv.25628. Epub 2019 Nov 21. J Med Virol. 2020. PMID: 31724212

2

Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.

Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, Feld JJ, de Knegt RJ, Wong DK, Janssen HL. Chi H, et al. Aliment Pharmacol Ther. 2015 May;41(9):867-76. doi: 10.1111/apt.13150. Epub 2015 Mar 5. Aliment Pharmacol Ther. 2015. PMID: 25752878

3

Flares during long-term entecavir therapy in chronic hepatitis B.

Chi H, Arends P, Reijnders JG, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Oo YH, Petersen J, van Bommel F, de Knegt RJ, Santantonio TA, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen BE, Janssen HL; VIRGIL Surveillance Study Group (European surveillance network for vigilance against viral resistance). Chi H, et al. J Gastroenterol Hepatol. 2016 Nov;31(11):1882-1887. doi: 10.1111/jgh.13377. J Gastroenterol Hepatol. 2016. PMID: 27008918

4

Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).

Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, Guo Q, Arends P, Wang JY, Verhey E, de Knegt RJ, Xie Q, Janssen HLA. Chi H, et al. J Infect Dis. 2017 Apr 1;215(7):1085-1093. doi: 10.1093/infdis/jix024. J Infect Dis. 2017. PMID: 28329061 Clinical Trial.

5

Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.

Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA, Peng J. Cao J, et al. Among authors: chi h. J Infect Dis. 2017 Feb 15;215(4):581-589. doi: 10.1093/infdis/jix025. J Infect Dis. 2017. PMID: 28329347

6

Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.

Chi H, Wong D, Peng J, Cao J, Van Hees S, Vanwolleghem T, Qi X, Chen L, Feld JJ, de Knegt RJ, Hansen BE, Janssen HLA. Chi H, et al. Clin Infect Dis. 2017 Aug 15;65(4):680-683. doi: 10.1093/cid/cix353. Clin Infect Dis. 2017. PMID: 28575292

7

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.

Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. Papatheodoridis GV, et al. Among authors: chi h. Hepatology. 2017 Nov;66(5):1444-1453. doi: 10.1002/hep.29320. Epub 2017 Oct 11. Hepatology. 2017. PMID: 28622419

8

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.

Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HLA, Berg T, Lampertico P. Papatheodoridis GV, et al. Among authors: chi h. J Hepatol. 2018 Jun;68(6):1129-1136. doi: 10.1016/j.jhep.2018.01.031. Epub 2018 Feb 8. J Hepatol. 2018. PMID: 29427727

9

Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.

Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Chi H, et al. Clin Gastroenterol Hepatol. 2019 Jan;17(1):182-191.e1. doi: 10.1016/j.cgh.2018.05.047. Epub 2018 Jun 11. Clin Gastroenterol Hepatol. 2019. PMID: 29902645

10

Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up.

van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. van Campenhout MJH, et al. Among authors: chi h. J Viral Hepat. 2019 Jan;26(1):109-117. doi: 10.1111/jvh.12997. Epub 2018 Sep 27. J Viral Hepat. 2019. PMID: 30187612

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,457 results

Search Page

Filters